Diagnos Inc.
- Company typePublic
- Founded2008
- HeadquartersBrossard, Canada
- Headcount—
- GTM typeB2B
- OfferingSoftware
Diagnos Inc. firmographics
Firmographics- Name
- Diagnos Inc.
- Legal name
- DIAGNOS Inc.
- Website
- https://diagnosmedical.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Ownership category
- akta.pro rank
Diagnos Inc. industry classification
Industry- Product category
- AI Medical Imaging Software
- NAICS
- Offices of Optometrists (621320), Optical Goods Retailers (45613)
- SIC
- Optical Instruments & Lenses (3827), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where Diagnos Inc. is headquartered
LocationHeadquarters
- HQ city
- Brossard
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Diagnos Inc. business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- AI Medical Analysis Services: DIAGNOS generates revenue through licensing its AI-powered retinal analysis platform (CARA System) to healthcare providers, hospitals, and clinics. Revenue is derived from multi-year contracts with healthcare networks and per-analysis fees.
- Technology Licensing: Licensing of proprietary AI algorithms and cloud-based medical analysis technology to partners including Essilor International and exclusive distribution partners in DACH/Europe regions.
- Professional Services: Implementation, training, and technical support services for healthcare facility deployment of AI screening solutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise licensing through multi-year contracts with healthcare providers |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Diagnos Inc. product offering
Product offeringCore offering
DIAGNOS develops and commercializes AI-powered retinal image analysis software (centered on its CARA System) for the early detection of diabetic retinopathy and other ocular diseases. The platform combines proprietary deep learning algorithms trained on 500,000+ retinal images with a real-time cloud-based analysis infrastructure, deployed to hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year licensing and subscription contracts.
Product overview
DIAGNOS offers a unified AI-powered medical device platform centered on its CARA System for retinal image analysis and early disease detection. The core offering consists of the CARA System (FDA/SFDA/Health Canada-cleared) working alongside the RetinaCare automated analysis module and the FLAIRE platform for AI-assisted medical diagnosis. The portfolio also includes a real-time cloud analysis platform and CARA STROKE (stroke risk assessment via retinal analysis). Together, these products enable AI-assisted early detection of ocular diseases and systemic health conditions through intelligent retinal imaging analysis.
Differentiator
Problem solved
Functional benefit
Brands
- CARA: AI-assisted screening platform for diabetic retinopathy and other ocular conditions.
- RetinaCare
- FLAIRE
- CARA STROKE
Products and services
- CARA System DIAGNOS' primary AI-powered medical device platform for retinal image analysis. The CARA System enables early detection of ocular diseases including diabetic retinopathy and supports clinical decision-making through automated analysis of retinal images with real-time cloud processing. Cleared by Health Canada and the Saudi FDA, and used by hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year contracts.
- FLAIRE Platform AI-based medical diagnosis platform referenced as DIAGNOS' broader AI technology for applying artificial intelligence to medical diagnosis beyond retinal screening. Used in support of the company's clinical AI portfolio.
- CARA STROKE Application extending DIAGNOS' retinal AI capabilities beyond ophthalmology to stroke and cardiovascular risk assessment through analysis of retinal images.
- Real-time Cloud Medical Analysis Platform Cloud-based platform enabling immediate, real-time processing and analysis of medical images with secure data handling, supporting the deployment of CARA System analysis at equipped healthcare centers.
Quantifiable outcome
- 500,000+ retinal images analyzed
- +3 more outcomes
Companies that use Diagnos Inc.
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
Diagnos Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Diagnos Inc. partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, flagship and minor.
- ÉTS Montreal (École de technologie supérieure)coreStrategic academic partnership with leading Montreal engineering school. Dr. Ismail Ben Ayed holds the AI in Medical Imaging Research Chair at ÉTS. Joint research and over $1 million federal funding announcement for next-generation retinal AI development. Collaboration involves training algorithms on millions of images from hospital and academic center partnerships.
- CISSS de la GaspésieflagshipRegional Quebec health network where DIAGNOS deployed its AI-assisted diabetic retinopathy screening across the healthcare network. Featured in Radio-Canada/ICI Gaspésie media coverage as a major deployment of AI screening technology in public healthcare.
- Essilor InternationalcoreMemorandum of understanding signed for potential collaboration with global optical lens leader. Represents strategic positioning for international expansion through major optical industry player.
- Exclusive DACH/Europe Distribution PartnercoreExclusive distribution agreement for DACH countries (Germany, Austria, Switzerland) and broader Europe, enabling access to significant European healthcare market through established distribution channels.
- IRIS / New Look Vision Group Inc.coreMulti-year agreement with major Canadian optical retail chain to integrate DIAGNOS AI technology across IRIS/New Look Vision retail locations, transforming optical retail into preventive screening hubs.
- Opticalia (Spain)minorPilot program in Spain testing DIAGNOS AI-powered eye screening technology with European optical retailer for potential broader deployment.
- Cielo Vista Eye Clinic (Mexico)core3-year contract with Mexican eye clinic for deployment of AI-powered retinal analysis services, representing established presence in Latin American market.
- Chaparral Medical Group (California)core3-year contract with California medical group for AI screening services deployment, representing U.S. market presence in healthcare screening.
- Juarez Health Medical Tourism ClustercoreMulti-year contract with medical tourism cluster for AI-assisted healthcare screening services targeting international patients.
- Optina Diagnosticscore3-year contract renewal with existing strategic partner for continued collaboration on AI-powered diagnostic solutions.
- Colombia Telemedecine CentreminorService agreement with Colombian telemedicine organization for deployment of DIAGNOS screening technology in Latin America.
- Magrabi HospitalcoreOfficial opening of AI-assisted screening clinic at Magrabi Hospital, establishing presence in Middle East healthcare market.
Scale indicators9 records
Recent moves6 records
Expansion highlights7 records
Diagnos Inc. competitors and assessment
Company assessmentDirect peers
- Eyenuk: Eyenuk's EyeArt AI system is an FDA-cleared autonomous diabetic retinopathy screening platform sold to primary care and optometry networks. Directly comparable to DIAGNOS' CARA in target use case (diabetic retinopathy screening) and customer base (eye care clinics, primary care).
- AEYE Health: AEYE Health provides FDA-cleared AI-based retinal screening for diabetic retinopathy with a single-image-per-eye workflow. Direct peer to DIAGNOS in autonomous AI screening sold to primary care and optometry channels.
- Digital Diagnostics (formerly IDx): Digital Diagnostics developed IDx-DR, the first FDA-cleared autonomous AI for diabetic retinopathy detection. Direct competitor to DIAGNOS in AI retinal screening for primary care and eye care settings, with similar clinical validation and regulatory positioning.
- RetinAI Medical (Ikerian): RetinAI Discovery is an AI platform for retinal image analysis and ophthalmology data management used in clinical research and screening workflows. Comparable to DIAGNOS in retinal AI analytics and clinical/research deployments.
Broad incumbents
- Optos (Nikon): Optos, owned by Nikon, provides ultra-widefield retinal imaging devices (optomap) used in diabetic retinopathy screening and ocular disease detection. Sells imaging hardware and integrated screening solutions across the same customer segments as DIAGNOS.
- Topcon Healthcare: Topcon is a major ophthalmic imaging and healthcare technology company whose Harmony/Imagenet clinical data platforms integrate with AI screening. Broader portfolio than DIAGNOS but operates in the same retinal imaging and screening ecosystem.
- Carl Zeiss Meditec (ZEISS Medical Technology): ZEISS Meditec is a major ophthalmic device and diagnostics company with CIRRUS OCT and integrated screening workflows. Broad incumbent in retinal imaging that DIAGNOS integrates with and competes against for clinical workflow budget.
- Heidelberg Engineering: Heidelberg Engineering is a global leader in OCT, confocal microscopy, and retinal imaging hardware used in ophthalmology. Provides the imaging devices DIAGNOS often integrates with and competes indirectly via their own AI workflows (Heidelberg AppWay).
Emerging players
- RetinaLyze System: RetinaLyze offers cloud-based AI screening for diabetic retinopathy and other retinal conditions, primarily serving European primary care and optometry. Overlaps with DIAGNOS in AI retinal screening use case, though at smaller commercial scale.
- Verily (Alphabet): Verily (an Alphabet company) has developed AI-driven retinal screening for diabetic retinopathy and cardiovascular risk assessment. A platform-scale emerging player whose capabilities overlap directly with DIAGNOS' CARA and CARA STROKE roadmaps.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Diagnos Inc. social profiles
Digital presenceDiagnos Inc. compliance and trust
Trust signalCompliance6 records
Diagnos Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diagnos Inc. leadership team
Management profileNumber of profiles
Profiles13 records
Diagnos Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diagnos Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diagnos Inc.
What does Diagnos Inc. do?
DIAGNOS develops and commercializes AI-powered retinal image analysis software (centered on its CARA System) for the early detection of diabetic retinopathy and other ocular diseases. The platform combines proprietary deep learning algorithms trained on 500,000+ retinal images with a real-time cloud-based analysis infrastructure, deployed to hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year licensing and subscription contracts.
Is Diagnos Inc. a public or private company?
Diagnos Inc. is a public company. It is classified as public and is currently operating.
When was Diagnos Inc. founded?
Diagnos Inc. was founded in 2008.
Where is Diagnos Inc. based?
Diagnos Inc. is headquartered in Brossard, Canada, in the North America region.
How does Diagnos Inc. make money?
Three revenue lines are on record. AI Medical Analysis Services are the primary driver. The others are technology Licensing and professional Services.
Who are Diagnos Inc.'s main competitors?
Direct peers on record are Eyenuk, AEYE Health, Digital Diagnostics (formerly IDx) and RetinAI Medical (Ikerian). Broad incumbents are Optos (Nikon), Topcon Healthcare, Carl Zeiss Meditec (ZEISS Medical Technology) and Heidelberg Engineering. Emerging players are RetinaLyze System and Verily (Alphabet).
Does Diagnos Inc. have an API?
No public API is recorded for Diagnos Inc..
What industry is Diagnos Inc. in?
Diagnos Inc.'s product category is AI Medical Imaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography). Its NAICS code is 621320 and its SIC code is 3827.